24/7 Patient Assistance: 760-405-8205

Hossein Borghaei, DO

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Lung Cancer Ovarian Cancer

specialties & services

  • Bio & Insurance Information

    Dr. Hossein Borghaei graduated medical school from Philadelphia College of Osteopathic Medicine and completed his residency program at Graduate Hospital. A fellowship in hematology/oncology followed at Temple University Hospital. Dr. Borghaei is both specialized and board certified in medical oncology. He has been in practice for more than 11 years and is affiliated with the Temple University Hospital. During his career, he had run several clinical trials and had also published multiple writings of medical interest in collaboration with other doctors.


  • Education & Training

    dept_icon

    Philadelphia College of Osteopathic Medicine Graduated in 1996

    Medical School

    dept_icon

    Philadelphia College of Osteopathic Medicine Completed in 1997

    Internship

    dept_icon

    Graduate Hospital-Tenet Healthcare

    Residency

    dept_icon

    Temple University Hospital

    Fellowship

  • Board Certifications

    American Board of Internal Medicine

  • Hospital & Practice

    Fox Chase Cancer Center

    Languages: English/Spanish

    (215) 728-6900

    7701 Burholme Ave

    Philadelphia, Pennsylvania 19111

    Read More

    Temple University Hospital

    Languages: English/Spanish

    (800) 836-7536

    3401 N Broad St

    Philadelphia, Pennsylvania 19140

    Read More
  • Publications & Memberships

    Dr. Hossein Borghaei has contributed to 3 publications.

    Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

    Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB

    See more >>

    Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer

    Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM

    See more >>

    Overcoming the KRAS resistance mechanism by augmenting antibody-dependent cellular cytotoxicity

    Hossein Borghaei, Barry Jones, Chris Kiritsy, Jack H Lai and William Bachovchin

    See more >>

    Memberships

    American Association for Cancer Research

    American Society of Clinical Oncology

    American Society of Hematology

    National Comprehensive Cancer Network